StockNews.com started coverage on shares of Avinger (NASDAQ:AVGR – Free Report) in a research report sent to investors on Thursday morning. The firm issued a hold rating on the medical device company’s stock.
Separately, HC Wainwright reaffirmed a buy rating and issued a $5.00 price target on shares of Avinger in a research note on Thursday, March 21st.
Read Our Latest Analysis on AVGR
Avinger Stock Performance
Avinger (NASDAQ:AVGR – Get Free Report) last released its quarterly earnings results on Wednesday, March 20th. The medical device company reported ($3.93) EPS for the quarter, missing analysts’ consensus estimates of $0.64 by ($4.57). The company had revenue of $1.91 million during the quarter, compared to analyst estimates of $2.52 million. On average, sell-side analysts predict that Avinger will post -2.08 earnings per share for the current year.
About Avinger
Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.
See Also
- Five stocks we like better than Avinger
- How to Calculate Inflation Rate
- MarketBeat Week in Review – 4/29 – 5/3
- What is a Special Dividend?
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Technology Stocks Explained: Here’s What to Know About Tech
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Avinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avinger and related companies with MarketBeat.com's FREE daily email newsletter.